Genmab — December 2023

[E_L]

"This data may support outpatient administration"

[E_L]

or as Abbvie states "This data may support investigating optimized step-up dose in an outpatient setting." https://news.abbvie.com/2023-12-09-New-Data-for-Bispecific-Antibody-Epcoritamab-DuoBody-R-CD3xCD20-Shows-Strong,-Durable-Treatment-Response-for-Patients-with-Difficult-To-Treat-Relapsed-Refractory-R-R-Follicular-Lymphoma-FL?utm_campaign=generic&utm_medium=social&utm_source=TW&utm_content=other&sf270770143=1

[Solsen]

It would be huge.

[nohope]

Hvor stor en patientgruppe er det i US/verden?

[Helge_LarsenPI-redaktør]

Godmorgen

[Stroka]

God morgen

[Klarussen]

Godmorgen. Håber flere af de "skrappe" drenge kommenterer på det her

[E_L]

Breaking new ground in #MultipleMyeloma #research!
@DrOlaLandgren
shares the analysis of the Phase 2 Centaurus Study, shedding light on the efficacy and safety of daratumumab monotherapy in patients with intermediate-risk or high-risk smoldering multiple #myeloma. #ASH23 https://twitter.com/SylvesterCancer/status/1733635907226391029 https://twitter.com/theMMRF/status/1733633272096469063 https://twitter.com/MM_Hub/status/1733651336317620661

[w]

80.000 NHL cases i US, 20-30% FL

[E_L]

real-world teclistamab experiences https://twitter.com/RahulBanerjeeMD/status/1733541272022139208 https://twitter.com/Abdallah81MD/status/1733541660137795678 https://twitter.com/MyelomaTeacher/status/1733551534586421315 https://twitter.com/Blood_Cancers/status/1733545210075136309

[E_L]

"This real world analysis is important since 80% of these pts wouldn’t have been eligible for the MagesTEC-1 trial" https://twitter.com/Curley_MD/status/1733548449336107277

[Klarussen]

@E L: can you perhaps explain for us novices in plain terms what it means forwardlooking, please?

[E_L]

Smoldering multiple myeloma is an early form of multiple myeloma that isn't cancer yet, which usually progresses to active myeloma, but at a slow rate. The jury is still out wether or not you should treat this already at this stage, or wait and see if it actually becomes MM and treat it then.

[E_L]

JNJ's Centaurus trial is one of the trials trying to state that you should start treating early with Daratumumab

[E_L]

Trials in general exclude a lot of patients based on criteria set by the investigator. This COULD give better results if patient selection is biased. The real world analysis for Teclistamab is of interest as these are patients treated in the real world outside of those trials, so without those stringent exclusion criteria where some patients are not allowed to participate.

[E_L]

And it shows that results are very similar to the trial, so that is good news as these results were very good

[Klarussen]

Thank you. This makes a lot of sense. Early intervention is better than later trying to cure

[E_L]

well, don't forget that there are also side effects of treatment AND that these treatments are very expensive, so you don't want to give them if you do not have a high degree of confidence that they actually help

[E_L]

unless you are JNJ, then you always want to sell them

[Klarussen]

Well my biggest concern with J&J is that, depending on the arbitrary case, they do not want to take CD38 further because there`s more profit and money invested in Darzalex for the time being, but thats another matter...